Janet Ellen Dancey
Queen's University · 326 works · 55,559 citations · h-index 81
Top works
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- Phase II Trial of Gefitinib in Recurrent Glioblastoma
- Recommendations for the assessment of progression in randomised cancer treatment trials
- Lessons learned from independent central review
- Validation of novel imaging methodologies for use as cancer clinical trial end-points
- RECIST 1.1—Update and clarification: From the RECIST committee
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
- Response assessment criteria for brain metastases: proposal from the RANO group
- Issues and progress with protein kinase inhibitors for cancer treatment
- Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
- Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy
- Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.
- Targeting epidermal growth factor receptor—are we missing the mark?
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma
- Strategies for optimizing combinations of molecularly targeted anticancer agents